| Patents for A61P 43 - Drugs for specific purposes, not provided for in groups (156,317) |
|---|
| 07/27/2005 | CN1646538A Topiramate salts and compositions comprising and methods of making and using the same |
| 07/27/2005 | CN1646535A Pyrrolopyrimidine derivative |
| 07/27/2005 | CN1646527A Medicaments containing BETAMIMETICS drugs and a novel anticholinesterase drug |
| 07/27/2005 | CN1646526A Tropane derivatives as CCR5 modulators |
| 07/27/2005 | CN1646525A Process for 5-[[2(R)-[1(R)-[3, 5-bis(trifluoromethyl)phenyl]ethoxy]-3(S)-(4-fluorophenyl)-4-morpholinyl]methyl]-1, 2-dihydro-3H-1, 2, 4-triazol-3-one |
| 07/27/2005 | CN1646520A 1, 3, 5-triazine derivatives as ligands for human adenosine-A3 receptors |
| 07/27/2005 | CN1646519A N-oxyde of N-phenyl-2-pyrimidine-amine derivatives |
| 07/27/2005 | CN1646516A Imidazolinylmethyl aralkylsulfonamides |
| 07/27/2005 | CN1646508A 5-substituted 1, 1-dioxo-1, 2, 5-thiazolidine-3-one derivatives as PTP ase 1B inhibitors |
| 07/27/2005 | CN1646505A Oxa- and thiadiazoles and their use as metalloproteinase inhibitors |
| 07/27/2005 | CN1646502A Triazole derivatives as tachykinin receptor antagonists |
| 07/27/2005 | CN1646500A Aryl substituted pyrimidines and the use thereof |
| 07/27/2005 | CN1646499A Fused pyridazine derivative compounds and drugs containing the compounds as the active ingredient |
| 07/27/2005 | CN1646493A 5HT2C receptor modulators |
| 07/27/2005 | CN1646480A Derivatives of hydroxyphenyl, a method for preparing thereof and their pharmaceutical composition |
| 07/27/2005 | CN1646473A Novel curcumin analogues and uses thereof |
| 07/27/2005 | CN1646460A 2-(2, 6-dichlorophenyl)-diarylimidazoles |
| 07/27/2005 | CN1646169A Injectable veterinary composition for small animals |
| 07/27/2005 | CN1646168A Co-therapy for the treatment of migraine comprising anticonvulsant derivatives and anti-migraine agents |
| 07/27/2005 | CN1646166A Method and composition for potentiating an opiate analgesic |
| 07/27/2005 | CN1646164A Process for the preparation of a nutrient formulation |
| 07/27/2005 | CN1646155A Cancer therapy |
| 07/27/2005 | CN1646153A Active antiangiogenic therapy |
| 07/27/2005 | CN1646142A Method of treating arrhythmias comprising administration of an A1 adenosine agonist with a beta blocker, calcium channel blocker or a cardiac glycoside |
| 07/27/2005 | CN1646138A Novel therapeutical use of agonist ligands specific to G2A receptor |
| 07/27/2005 | CN1646137A Method for treating and preventing hyperparathyroidism |
| 07/27/2005 | CN1646133A Pharmaceutical combinations of cox-2 inhibitors and opiates |
| 07/27/2005 | CN1646131A Novel compounds |
| 07/27/2005 | CN1646126A Medicaments containing steroids and a novel anticholinesterase drug |
| 07/27/2005 | CN1646124A Use of materials having zinc ionophoric behavior |
| 07/27/2005 | CN1646120A Antineoplastic combinations |
| 07/27/2005 | CN1646119A Therapeutic methods and compositions involving isoflav-3-ene and isoflavan structures |
| 07/27/2005 | CN1646115A Treating benign prostate hyperplasia with SARMS |
| 07/27/2005 | CN1646111A Novel association of an antithrombotic agent with aspirin and use thereof for treating atherothrombotic diseases |
| 07/27/2005 | CN1646097A Chemosensitizing with liposomes containing oligonucleotides |
| 07/27/2005 | CN1646095A Inhalation kit comprisung inhalable powder of tiotropium |
| 07/27/2005 | CN1646078A Composition for cell proliferation |
| 07/27/2005 | CN1644693A Protein having tpo activity |
| 07/27/2005 | CN1644203A Oral preparation of red common stone crop polysaccharide and its making method |
| 07/27/2005 | CN1644201A Application of folic acid-containing pharmaceutical compositions |
| 07/27/2005 | CN1212398C Novel IFN receptor 1 binding proteins, DNA encoding them, and method of modulating cellular response to interferons |
| 07/27/2005 | CN1212166C Safety shield system for prefilled syringes |
| 07/27/2005 | CN1212149C Chinese medicine preparation for curing children's hyperkinetic symptom and its preparing process |
| 07/27/2005 | CN1212139C Preparation for treating chronic exhaustion syndrome and its preparing process |
| 07/27/2005 | CN1212138C Anti-senility medicine and its preparation |
| 07/27/2005 | CN1212117C Medicine composition for treating diabetes mellitus |
| 07/26/2005 | US6921826 Thioether substituted imidazoquinolines |
| 07/26/2005 | US6921821 Antagonists of melanin concentrating hormone receptor |
| 07/26/2005 | US6921763 Protein kinase inhibitors |
| 07/26/2005 | US6921760 Psychotherapeutic agents. |
| 07/26/2005 | US6921757 Conversion of carboxylic acid substituent in a gonane ring, into the methyl ester, or hydrochlorination of a 9-11-epoxy-9-H-cyclopenta(a)phenanthrene compounds |
| 07/26/2005 | US6921749 Polypeptides derived from endostatin exhibiting antiangiogenic activity |
| 07/26/2005 | US6921650 Recombinant methods and materials for producing epothilone and epothilone derivatives |
| 07/26/2005 | US6921541 Formulations and methods for providing prolonged local anesthesia |
| 07/26/2005 | CA2315481C Selective inhibition of aggrecanase in osteoarthritis treatment |
| 07/26/2005 | CA2256609C 5-aroylpyrrol-2-ylmethylarene derivatives as inhibitors of prostaglandin g/h synthase |
| 07/26/2005 | CA2253948C Carboline derivatives |
| 07/26/2005 | CA2234642C 3,4-diaryl-2-hydroxy-2,5-dihydrofurans as prodrugs to cox-2 inhibitors |
| 07/26/2005 | CA2193388C Aryl and heteroaryl alkoxynaphthalene derivatives |
| 07/26/2005 | CA2175498C Phenylindole compounds |
| 07/26/2005 | CA2152902C Selective ligands of receptors 5-ht1d-5ht1b derived from indole-piperazine useful as medicaments |
| 07/26/2005 | CA2152630C Enantiomers of carbazole derivatives as 5-ht1-like agonists |
| 07/26/2005 | CA2149007C Cyclohexane derivatives, process for their preparation, and the use of the compounds for the treatment of diseases |
| 07/26/2005 | CA2133439C Compounds useful for treating allergic and inflammatory diseases |
| 07/26/2005 | CA2112011C Substituted pyridines |
| 07/21/2005 | WO2005066410A1 Allergen suppressor, allergen-suppression processed fiber and method of producing the same |
| 07/21/2005 | WO2005066357A1 Method of screening molecule associated with psychiatric disorder |
| 07/21/2005 | WO2005066193A1 Levulose glucoselipid a analogue |
| 07/21/2005 | WO2005065704A1 Preventive and remedy for bone disease |
| 07/21/2005 | WO2005039638A3 Therapeutic agent for heart failure comprising an angiotensin ii receptor antagonist and a matrix metalloproteinase inhibitor |
| 07/21/2005 | WO2005026137A3 Modulators of atp-binding cassette transporters |
| 07/21/2005 | US20050159611 Process for producing shogaols and intermediates for the synthesis thereof |
| 07/21/2005 | US20050159598 Activators of human peroxisome proliferator activated receptors such as {2-[2-fluoro-4-(trifluoromethyl)phenyl]-4-methyl-1,3-thiazol-5-yl}methanol |
| 07/21/2005 | US20050159589 Process for the purification and/or isolation of biologically active granulocyte colony stimulating factor |
| 07/21/2005 | US20050159585 Forming acyl azide function on acid group of amino acid derivative, then transforming to isocyanate |
| 07/21/2005 | US20050159584 O-succinimidyl-2-[(9H-fluoren-9-ylmethoxy)carbonylamino]-ethylcarbamate's used as monomers active in the synthesis of di- and tri-substituted ureas and urea oligomers |
| 07/21/2005 | US20050159493 Alzheimer's disease; small molecule amine salts |
| 07/21/2005 | US20050159492 Enhancing bioavailability of oral immediate release tablets for low solubility medicants; respiratory inflammatory disorders |
| 07/21/2005 | US20050159480 Preparation of statins by reacting (trisubstituted phosphoranylidenecarbonyl)acetates with benzaldehydes, reduction with diamino-group 8 metal coordinates, condensation with 1-hydroxy-1-alkoxyethylenes, hydrolysis, and optionally converting the carboxy acid product into a salt or a lactone |
| 07/21/2005 | US20050159472 Chemical compounds |
| 07/21/2005 | US20050159467 5-Aryltetrazole compounds and uses thereof |
| 07/21/2005 | US20050159462 Elevates extracellular adenosine concentration for antiinflammatory and immunosuppressive effects; reaction of imidazole-4-carboxamide with a hydroxyalkylbenzoxazole or benzothiazole compound; 1-[4-hydroxy-1-(2-phenyl-4-benzoxazolyl)-3-pentyl]-imidazole-4-carboxamide |
| 07/21/2005 | US20050159461 Treating cancer with a synergistic mixtures; anticarcinogenic agents; epothilone has secondary amide instead of an ester |
| 07/21/2005 | US20050159460 2-[(1R,3S,4S)-1-benzyl-4-t-butoxycarbonylamino-3-hydroxy-5-phenylpentyl]-5-butyl-thiazole; for inhibiting beta-secretase-mediated cleavage of amyloid precursor protein, particularly to inhibit production of A beta peptide; treatment of diseases associated with a pathological form of A beta peptide |
| 07/21/2005 | US20050159459 inhibitors of the beta-secretase enzyme that are useful in the treatment of Alzheimer's disease and other diseases characterized by deposition of A beta peptide in a mammal. The compounds of the invention are useful to reduce forming beta peptides |
| 07/21/2005 | US20050159457 Aminopyridinyl-, aminoguanidinyl- and alkoxyguanidinyl-substituted phenyl acetamides as protease inhibitors |
| 07/21/2005 | US20050159452 Nociceptin analogs |
| 07/21/2005 | US20050159451 NMDA (N-methyl-D-aspartate) receptors; eg 6-(4-benzylpiperidin-1-carbonyl)-1,5-dihydro-oxazolo[4,5-f]indole-2-one |
| 07/21/2005 | US20050159450 Derivative of n-[phenyl(piperidin-2-yl)methyl]benzamide, the preparation method thereof and application of same in therapeutics |
| 07/21/2005 | US20050159445 Selective iGluR5 receptor antagonists |
| 07/21/2005 | US20050159443 For example, N-[2,4-dichloro-3-(2-methyl-quinolin-8-yloxymethyl)-phenyl]-N-methyl-2-[1-methyl-5-(3-methyl-4-nitro-benzoyl)-1H-pyrrol-2-yl]-acetamide; bradykinin receptor agonists; for treating disorders such as pain, inflammation, asthma and allergy |
| 07/21/2005 | US20050159441 Active ingredient and solvent can be stored separately until apparatus is used in a nebuliser; propellant-free; active ingredient is present in highly-concentrated form for storage purposes; inhalers |
| 07/21/2005 | US20050159437 Pharmaceutical agents |
| 07/21/2005 | US20050159435 [3-Methyl-4-(pyridin-3-yloxy)-phenyl]-(6-piperidin-3-ylethynyl-quinazolin-4-yl)-amine; selective inhibitors of receptor tyrosine kinases and non-receptor tyrosine kinases (eg: Ick, src, abl) or serine/threonine kinases (e.g.: cyclin dependent kinases); carcinoma |
| 07/21/2005 | US20050159434 3-{(3R,4R)-4-methyl-3-[methyl-(7H-pyrrolo[2,3-d]pyrimidin-4-yl)-amino]-piperidin-1-yl)-3-oxo-propionitrile mono citrate salt; immunosuppressants, autoimmune diseases, skin disorders, Crohn's disease, antidiabetic agents, anticancer agents, antiarthritic agents |
| 07/21/2005 | US20050159426 Novartis drug called Imatinib, 4-(4-methylpiperazin-1-ylmethyl)-N-[4-methyl-3-(4-pyridin-3-yl)pyrimidin-2-ylamino)phenyl]-benzamide, methanosulfonate; synergistic mixture with a second antineoplastic agent |
| 07/21/2005 | US20050159425 Inducing tolerance to an antigen by administering to patient a prostaglandin or agonist thereof, a phosphodiesterase inhibitor, and antigen or a derivative thereof; suppressing immune system or an inflammatory response; for example, use of misoprostol and rolipram; antiinflammatory agents, antiallergens |
| 07/21/2005 | US20050159422 Inhibitors of akt activity |
| 07/21/2005 | US20050159421 Ethylene diamine derivatives and their use as orexin-receptor antagonists |
| 07/21/2005 | US20050159418 Nitrogen compounds used as xanthine oxidase inhibitors, for prophylaxis of inflammation, reperfusion injuries, gout or inflammatory bowel disorders |